BioCryst Pharmaceuticals, Inc. $BCRX Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 21.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,542,714 shares of the biotechnology company’s stock after purchasing an additional 448,436 shares during the period. BNP Paribas Financial Markets’ holdings in BioCryst Pharmaceuticals were worth $19,833,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after purchasing an additional 482,494 shares during the period. Deerfield Management Company L.P. increased its position in BioCryst Pharmaceuticals by 159.4% during the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after purchasing an additional 7,477,000 shares during the last quarter. State Street Corp boosted its stake in BioCryst Pharmaceuticals by 8.9% during the second quarter. State Street Corp now owns 8,505,392 shares of the biotechnology company’s stock worth $76,208,000 after buying an additional 691,988 shares during the period. Arrowstreet Capital Limited Partnership boosted its stake in BioCryst Pharmaceuticals by 22.1% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,225,986 shares of the biotechnology company’s stock worth $39,665,000 after buying an additional 947,431 shares during the period. Finally, Two Sigma Investments LP boosted its stake in BioCryst Pharmaceuticals by 3.1% during the third quarter. Two Sigma Investments LP now owns 4,419,629 shares of the biotechnology company’s stock worth $33,545,000 after buying an additional 131,406 shares during the period. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $8.41 on Friday. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of -4.72 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.23. The firm has a fifty day moving average price of $9.03 and a two-hundred day moving average price of $8.06.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the company posted $0.20 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 150,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the sale, the insider directly owned 400,703 shares in the company, valued at $3,666,432.45. The trade was a 27.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BCRX shares. Citizens Jmp lifted their price target on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Thursday, May 7th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Wedbush dropped their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday. Finally, Needham & Company LLC decreased their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $20.70.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.